The Patient Protection and Affordable Care Act adds a new provision to the Internal Revenue Code that could provide a significant benefit to small and mid-size companies in the biotechnology industry. The Act, which was signed by President Obama on March 23, authorizes the Secretary of the Treasury to award up to $1 billion in qualifying therapeutic discovery project credits in 2009 and 2010. The credit is equal to 50% of an eligible taxpayer’s qualified investment in a qualifying therapeutic discovery project.
Qualifying therapeutic discovery projects include projects that are designed to treat, prevent, or diagnose diseases or conditions, as well as projects designed to develop products, processes or technologies to further the delivery or administration of therapeutics. Taxpayers must apply to receive the credit, and any taxpayer with 250 or fewer employees is eligible to submit an application. In lieu of the tax credit, eligible taxpayers can apply for a grant equal to 50% of the taxpayer’s qualified investment.
The Act requires the Secretary of the Treasury, in conjunction with the Department of Health and Human Services, to establish a program to consider and certify qualified investments no later than May 21, 2010. Therefore, regulations detailing the required form and content of the credit and grant applications will likely be released in mid-May. In the meantime, there are several steps that taxpayers in the biotech industry could take to prepare for the application process, including evaluating current and planned projects to determine which projects could qualify for the credit and itemizing qualified investment expenses.
For detailed information about the credit, click here.
For media coverage on the topic, click here.
- Partner
Mark Sims practices in the Business Representation & Transactions Group and works primarily in the federal income tax, business planning and healthcare areas. Mark's federal tax practice involves individual, corporate, S ...
Topics/Tags
Select- Securities Law
- Securities Regulation
- SEC
- Corporate Transparency Act
- Corporate Law
- Clawback Rules
- Nasdaq
- SEC Enforcement
- Coronavirus
- Cybersecurity and Privacy Law
- Mergers & Acquisitions
- Dodd-Frank
- Tax Planning
- IRS
- Economic Sanctions
- Paycheck Protection Program
- Ohio LLC Act
- Corporate Tax
- JOBS Act
- FAST Act
- Corporate Governance
- Proxy Access Rules
- Securities Litigation
- Consumer Protection Act
- Cybersecurity Regulation
- Crowdfunding
- Cryptocurrency
- Hedging
- Conflict Minerals
- Real Estate Law
- Emerging Growth Companies
- Investors
- Taxation
- Pay Ratio Disclosure
- Private Offerings
- Whistleblower
- Intellectual Property
- Technology
- LIBOR
- Opportunity Zone
- Accredited Investors
- Sales Tax
- United States Supreme Court
- Executive Compensation
- Health Care Act
- Online Trading Platforms
- IPO
- Registration Statement
- Wall Street Reform
- Annual Reports
- Ohio Foreclosure Reform
- Director Compensation
- Family-Controlled Entities
- Gift and Estate Transfers
- Board of Directors
- Director Independence
- Cyber Insurance
- Data Breach
- Regulation A
- Regulation D
- Total Shareholder Return
- Lenders
- Receivership Statute
- Compensation Committee Certification
- CDEs
- CDFI Fund
- Community Development Entities
- Community Development Financial Institutions Fund
- Government Shutdown
- New Markets Tax Credit
- NMTC
- NMTC Financing
- Regulation Fair Disclosure
- Social Media
- Benefits
- Healthcare Reform
- Litigation
- Marketing
- Public Company Transition Rules
- Employment Incentives
- HIRE Act
- Social Security Tax
- Tax Credit
Recent Posts
- FinCEN Extends the Corporate Transparency Act Reporting Deadline for Newly Created Entities
- SEC Postpones Share Repurchase Modernization Disclosure Rules
- Effective Date of SEC Clawback Rule Finally In Sight
- SEC Sued Over Newly Adopted Share Repurchase Rules
- SEC Extends Period to Act on Exchange Clawback Rules
- SEC Charges Public Company for Misleading Non-GAAP Disclosures
- NYSE and Nasdaq Propose Clawback Listing Standards: What You Need to Know
- Corporate Transparency Act Update – FinCEN Issues Notice of Proposed Rulemaking
- SEC Amends Insider Trading Rules: New Conditions, Requirements, and Related Disclosures
- SEC Reopens Comment Period for 11 Proposed Rules Due to Technological Error